Clinical momentum Remedy Plan Therapeutics is advancing RPT1G into the clinic in 2024 with a first-in-human Phase 1 healthy volunteer study already completed, signaling readiness for potential collaboration, co-development, or sponsored research opportunities in NAMPT inhibition for hematologic malignancies and solid tumors.

Strategic leadership Recent hires at the C-suite and board level, including a new chief financial and business officer and an acting CMO plus independent directors, create opportunities to engage in strategic partnerships, licensing discussions, and potential investment or joint venture conversations.

Financing signals A disclosed $18M financing round and an overall funding of $47M indicate active investor interest and an appetite for partnerships to accelerate development, offering avenues for co-development deals, milestone-based collaborations, or equity-backed alliances.

Pipeline focus A robust NAMPT inhibitor program with tunable hyperbolic activity across oncology and metabolic/autoimmune indications provides multiple entry points for strategic collaborations, CRO/CDMO support, or platform licensing to accelerate preclinical-to-clinic timelines.

Industry positioning Participation in high-profile venues like AACR and emphasis on addressing on-target toxicity challenges positions Remedy Plan as a potential partner for research collaborations, contract study work, and shared risk ventures in translational NAMPT research.